Novartis To Buy US Biotech In Up-To-$2B Allergy Drug Deal
Swiss pharmaceutical giant Novartis AG said Friday that it will buy Excellergy, a U.S. biotechnology company, for up to $2 billion as it seeks access to a therapy to combat allergic reactions....To view the full article, register now.
Already a subscriber? Click here to view full article